Olmecip H Tablet contains a combination of Hydrochlorothiazide (12.5 mg) and Olmesartan Medoxomil (20 mg), indicated for the management of hypertension. Olmesartan Medoxomil is an angiotensin II receptor antagonist that selectively blocks the binding of angiotensin II to the AT1 receptor, thereby inhibiting vasoconstriction and aldosterone secretion, leading to vasodilation and reduced blood pressure. Hydrochlorothiazide is a thiazide diuretic that promotes diuresis by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys, resulting in decreased plasma volume and peripheral vascular resistance. The combination of these two agents provides complementary mechanisms to effectively control elevated blood pressure, reducing the risk of cardiovascular events such as stroke, myocardial infarction, and heart failure. Olmecip H is typically prescribed when monotherapy with either component is insufficient to achieve target blood pressure goals. It is important to monitor renal function, electrolytes, and blood pressure regularly during therapy. Contraindications include hypersensitivity to sulfonamide-derived drugs, severe renal impairment, and pregnancy. Patients should be advised to maintain adequate hydration and report symptoms such as dizziness or muscle weakness. Olmecip H Tablet should be used under medical supervision with appropriate dose adjustments based on clinical response.